Here are three quick facts.
1. Seven analysts rated the company’s stock as “buy,” seven rated it as “outperform,” and 11 rated it as “hold.”
2. Analysts have a consensus estimate of $0.88 per share.
3. Some Thomas/First Call analysts projected a price target of $71, which would be a 31 percent upside potential from the closing price of $54.04.
More articles on devices:
Plaintiffs win $502M verdict against Johnson & Johnson over hip device — 5 things to know
Touch Surgery, Zimmer Biomet launch Oxford Partial Knee training — 4 points
Life Spine sales jump 45% in 6 months: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
